As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional 15%, or 1.35m shares, of the common stock offered in the public offering.
All of the shares to be sold in the offering are to be sold by Proteostasis.
Proteostasis is dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera